Working… Menu

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00973076
Recruitment Status : Completed
First Posted : September 9, 2009
Last Update Posted : June 15, 2011
Information provided by:

Brief Summary:
The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.

Condition or disease Intervention/treatment Phase
Cancer Solid Tumors Advanced Solid Malignancies Drug: AZD8055 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open Label, Single-centre Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 Administered Orally to Japanese Patients With Advanced Solid Tumours
Study Start Date : August 2009
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Arm Intervention/treatment
Experimental: AZD8055
AZD8055 will be administered orally
Drug: AZD8055
Tablets, orally administered, twice daily

Primary Outcome Measures :
  1. Assessment of adverse events, clinical laboratory tests (clinical chemistry, haematology, coagulation, urinalysis), glucose management (s-glucose, s-insulin, haemoglobin A1c [HbA1c]), vital signs (pulse rate, blood pressure, weight and body temperature) [ Time Frame: Laboratory values, vital sign, physical examination every week during Cycle 1 and 2. ]

Secondary Outcome Measures :
  1. To determine the pharmacokinetic profile of AZD8055 following both single and multiple oral dosing in patients with advanced solid tumours [ Time Frame: According to protocol specified schedule, the number of PK samples collected during Cycle 1 ]
  2. To seek preliminary evidence of the anti-tumour activity of AZD8055 in patients with advanced solid malignancies as measured by objective tumour response (according to RECIST criteria) [ Time Frame: Every cycle ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Japanese patients with advanced solid tumors for which suitable effective standard treatment does not exist or is no longer effective
  • Relatively good overall health other than cancer

Exclusion Criteria:

  • Poor bone marrow function (not producing enough blood cells)
  • Poor liver or kidney function
  • Serious concomitant illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00973076

Layout table for location information
Research Site
Tokyo, Japan
Sponsors and Collaborators
Layout table for investigator information
Study Director: Ian Smith AstraZeneca
Principal Investigator: Tomohide Tamura National Cancer Center Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: MSD, AstraZeneca Pharmaceuticals Identifier: NCT00973076    
Other Study ID Numbers: D1600C00003
First Posted: September 9, 2009    Key Record Dates
Last Update Posted: June 15, 2011
Last Verified: June 2011
Keywords provided by AstraZeneca:
Phase I, cancer
solid tumors
advanced solid malignancies
dose escalation
mTOR Kinase Inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms